Author

OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Calendar

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Bristol-Myers Squibb and Sanofi-Aventis Prevail Over Apotex in Plavix Case | Main | Informa Life Sciences "Legal Strategies for Developing Generic Medicines" Conference, July 9-11, Amsterdam, The Netherlands »

June 23, 2007

Pharma News Briefs

  • Pharmalot had this post Friday about a new bipartisan follow-on biologics bill in the Senate.
  • MarketWatch reported Friday that European regulators have moved a step closer to approving Sandoz's follow-on version of J&J's blockbuster Eprex, sold in the U.S. as Procrit.
  • On Thursday, a House committee marked up the PDUFA reauthorization legislation (Pharmalot).  PhRMA reacted positively in this press release.
  • FDA Law Blog had this post Tuesday reporting that the Senate-passed version of FDARA would open the door to 5-year New Chemical Entity exclusivity for enantiomers of previously-approved racemic drug compounds.

Posted by Aaron Barkoff in Biosimilars, Pharma Business News |

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.